Plaque Psoriasis Clinical Study (smartwatch)

We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.

About Plaque Psoriasis

Psoriasis is a chronic inflammatory skin disease characterized by raised, red oval plaques on the skin with silvery scales. Lesions are typically painful or itchy and can be associated with a high degree of morbidity. Plaques on visible skin have a particular impact on physical, sexual, psychosocial, and even economic status; associated with reduced levels of employment and income. Psoriasis is more than a superficial disease, with 30% of patients having joint involvement, and a high correlation between psoriasis and obesity, diabetes, depression, metabolic syndrome, and cardiovascular risk.

About the Study

We are seeking patients that meet the below criteria to participate in a 56-week study to evaluate the safety and efficacy of Deucravacitinib (oral tablet) versus placebo in adult subjects with moderate to severe psoriasis.

Am I Eligible?

• Males and females ages 18 and older
• History of plaque psoriasis in the past 6 months
• Must have psoriasis involvement of 3% or greater of body surface area (1% is approximately equivalent to the size of your palm)
• Be available for 16 office visits over a 52-week treatment period, and a 4-week follow-up period
• Willing to wear smartwatch for 2 weeks to record sleep activity

Other Information 

No health insurance required, all study procedures provided at no cost to you. Compensation may be provided for your time/travel.

If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.